Caraway Therapeutics, Inc.

Biotechnology ResearchUnited States11-50 Employees

A TARGETED APPROACH TO ACTIVATE CELLULAR CLEARANCE
Caraway’s therapeutic approach leverages genetic data and unique biological understanding to develop proprietary small molecules that activate cellular clearance and recycling processes – accelerating clearance of accumulated toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal function and pathologies in multiple organ systems, including the central nervous system (CNS), heart, kidney, and muscle.  Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).
        

 
        
            Show more
          

          


 
        
            Show less

Sign up for free to view info

Email Format Employee directory